Cargando…

Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones

BACKGROUND: The direct effects of etomidate were investigated on the secretion of cortisol and its precursors by dispersed cells from the adrenal cortex of human of animals. Dexmedetomidine (DEX) is an anesthetic agent that may interfere with cortisol secretion via an unknown mechanism, such as invo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Hongbin, Zhang, Mazhong, Cai, Meihua, Liu, Jinfen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654590/
https://www.ncbi.nlm.nih.gov/pubmed/26568275
http://dx.doi.org/10.12659/MSM.894728
_version_ 1782402082575220736
author Gu, Hongbin
Zhang, Mazhong
Cai, Meihua
Liu, Jinfen
author_facet Gu, Hongbin
Zhang, Mazhong
Cai, Meihua
Liu, Jinfen
author_sort Gu, Hongbin
collection PubMed
description BACKGROUND: The direct effects of etomidate were investigated on the secretion of cortisol and its precursors by dispersed cells from the adrenal cortex of human of animals. Dexmedetomidine (DEX) is an anesthetic agent that may interfere with cortisol secretion via an unknown mechanism, such as involving inhibition of 11β-hydroxylase and the cholesterol side-chain cleavage enzyme system. The aim of this study was to determine whether dexmedetomidine (DEX) has a similar inhibitory effect on adrenocortical function, and whether combined use of etomidate (ETO) and DEX could produce a synergistic action in inhibiting the secretion of human adrenocortical hormones. MATERIAL/METHODS: Human adrenocortical cells were exposed to different concentrations of ETO and DEX. The dose-effect model between the ETO concentration and the mean secretion of cortisone (CORT) and aldosterone (ALDO) per hour was estimated. RESULTS: Hill’s equation well-described the dose-effect correlation between the ETO concentration and the amount of ALDO and CORT secretion. When the DEX concentration was introduced into the model by using E(0) (basal secretion) as the covariate, the goodness of fit of the ETO-CORT dose-effect model was improved significantly and the objective function value was reduced by 4.55 points (P<0.05). The parameters of the final ETO-ALDO pharmacodynamics model were EC(50)=9.74, E(max)=1.20, E(0)=1.33, and γ=18.5; the parameters of the final ETO-CORT pharmacodynamics model were EC(50)=9.49, E(max)=8.16, E(0)=8.57, and γ=37.0. In the presence of DEX, E(0) was 8.57–0.0247×(CDEX–4.6), and the other parameters remained unchanged. All parameters but γ were natural logarithm conversion values. CONCLUSIONS: Combined use of DEX and ETO reduced ETO’s inhibitory E(0) (basal secretion) of CORT from human adrenocortical cells in a dose-dependent manner, suggesting that combined use of ETO and DEX produced an additive effect in inhibiting the secretion of human adrenocortical hormones.
format Online
Article
Text
id pubmed-4654590
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-46545902015-12-02 Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones Gu, Hongbin Zhang, Mazhong Cai, Meihua Liu, Jinfen Med Sci Monit Lab/In Vitro Research BACKGROUND: The direct effects of etomidate were investigated on the secretion of cortisol and its precursors by dispersed cells from the adrenal cortex of human of animals. Dexmedetomidine (DEX) is an anesthetic agent that may interfere with cortisol secretion via an unknown mechanism, such as involving inhibition of 11β-hydroxylase and the cholesterol side-chain cleavage enzyme system. The aim of this study was to determine whether dexmedetomidine (DEX) has a similar inhibitory effect on adrenocortical function, and whether combined use of etomidate (ETO) and DEX could produce a synergistic action in inhibiting the secretion of human adrenocortical hormones. MATERIAL/METHODS: Human adrenocortical cells were exposed to different concentrations of ETO and DEX. The dose-effect model between the ETO concentration and the mean secretion of cortisone (CORT) and aldosterone (ALDO) per hour was estimated. RESULTS: Hill’s equation well-described the dose-effect correlation between the ETO concentration and the amount of ALDO and CORT secretion. When the DEX concentration was introduced into the model by using E(0) (basal secretion) as the covariate, the goodness of fit of the ETO-CORT dose-effect model was improved significantly and the objective function value was reduced by 4.55 points (P<0.05). The parameters of the final ETO-ALDO pharmacodynamics model were EC(50)=9.74, E(max)=1.20, E(0)=1.33, and γ=18.5; the parameters of the final ETO-CORT pharmacodynamics model were EC(50)=9.49, E(max)=8.16, E(0)=8.57, and γ=37.0. In the presence of DEX, E(0) was 8.57–0.0247×(CDEX–4.6), and the other parameters remained unchanged. All parameters but γ were natural logarithm conversion values. CONCLUSIONS: Combined use of DEX and ETO reduced ETO’s inhibitory E(0) (basal secretion) of CORT from human adrenocortical cells in a dose-dependent manner, suggesting that combined use of ETO and DEX produced an additive effect in inhibiting the secretion of human adrenocortical hormones. International Scientific Literature, Inc. 2015-11-16 /pmc/articles/PMC4654590/ /pubmed/26568275 http://dx.doi.org/10.12659/MSM.894728 Text en © Med Sci Monit, 2015 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Lab/In Vitro Research
Gu, Hongbin
Zhang, Mazhong
Cai, Meihua
Liu, Jinfen
Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones
title Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones
title_full Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones
title_fullStr Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones
title_full_unstemmed Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones
title_short Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones
title_sort combined use of etomidate and dexmedetomidine produces an additive effect in inhibiting the secretion of human adrenocortical hormones
topic Lab/In Vitro Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654590/
https://www.ncbi.nlm.nih.gov/pubmed/26568275
http://dx.doi.org/10.12659/MSM.894728
work_keys_str_mv AT guhongbin combineduseofetomidateanddexmedetomidineproducesanadditiveeffectininhibitingthesecretionofhumanadrenocorticalhormones
AT zhangmazhong combineduseofetomidateanddexmedetomidineproducesanadditiveeffectininhibitingthesecretionofhumanadrenocorticalhormones
AT caimeihua combineduseofetomidateanddexmedetomidineproducesanadditiveeffectininhibitingthesecretionofhumanadrenocorticalhormones
AT liujinfen combineduseofetomidateanddexmedetomidineproducesanadditiveeffectininhibitingthesecretionofhumanadrenocorticalhormones